

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>99,134-A</b>	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/US00/06371</b>	International filing date ( <i>day/month/year</i> ) <b>10/03/2000</b>	Priority date ( <i>day/month/year</i> ) <b>11/03/1999</b>	
International Patent Classification (IPC) or national classification and IPC <b>C07D471/00</b>			
Applicant <b>NEUROGEN CORPORATION et al.</b>			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
  
2. This REPORT consists of a total of 6 sheets, including this cover sheet.
 

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of    sheets.

3. This report contains indications relating to the following items:
 

I    ☒ Basis of the report

II   ☐ Priority

III   ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability


IV   ☐ Lack of unity of invention

V    ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

VI   ☒ Certain documents cited

VII   ☐ Certain defects in the international application

VIII   ☒ Certain observations on the international application

Date of submission of the demand  <b>28/09/2000</b>	Date of completion of this report  <b>11.05.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  <b>Baston, E</b>  Telephone No. +49 89 2399 8229



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/06371

**1. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-54 as originally filed

**Claims, No.:**

1-45 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/06371

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 33,36-40 "with respect to industrial applicability", 45.

because:

- ☒ the said international application, or the said claims Nos. 33,36-40 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
- ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 45 are so unclear that no meaningful opinion could be formed (*specify*):  
**see separate sheet**

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims 1-44
	No: Claims
Inventive step (IS)	Yes: Claims 1-44
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-32,34,35,41-44

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/06371

---

No: Claims

2. Citations and explanations  
**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/06371

**To section III**

Claims 33 and 36-40 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Claim 45 is not clear (Art. 6 PCT), since the indication of the inhibitory potency ( $IC_{50}$  of 1 micromolar or less) is a relative parameter which strongly depends on the assay conditions. Consequently this value is meaningless and is not considered to represent a specification, which would encompass a subject-matter of a narrower scope.

**To section V**

The following document was cited in the search report and was considered for the examination of the present application:

D1: WO 97 19926 A

The present application is related to aryl-fused pyridine derivatives, which are considered to have NK3-receptor affinity and might therefore be useful for the treatment of e.g. CNS-related diseases. The aryl-group in the aforementioned structure contains at least one nitrogen atom, which distinguishes the presently claimed compounds from the prior art D1 (quinoline-derivatives with affinity for the NK-2 and NK-3 receptor). Compounds from D1 are excluded from the present application via disclaimer (page 57, line 6,7).

Consequently the subject-matter of claims 1-32,43,44 (compounds, compositions), 34-35 (use) and 33,36-42 (methods) is novel (Art. 33(2) PCT).

Claims 1-44 involve an inventive step (Art. 33(3) PCT), since the prior art does not teach or suggest, that the replacement of the phenyl-ring in the quinoline basic structure by other N-heterocycles leads to active congeners as well.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/06371

For the assessment of the present claims 33 and 36-40 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**To section VI**

D2: GIARDINA, G. A. M. ET AL: 'Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists' FARMACO (1999), 54(6), 364-374

This document is related to quinoline derivatives, which were shown to possess NK-3 receptor antagonism activity. Some compounds of this publication (table 1, cpds. 10-12 and 14) fall within the scope of claim 1 of the present application. Consequently D2 might become relevant for novelty and inventive step in the national/European phase if the priority date was invalid.

**To section VIII**

D1 is considered to represent relevant state of the art (compare the disclaimer of claim 1) and should be cited in the description (Rule 5.1(a)(iii)).